Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 12;13(8):2256.
doi: 10.3390/jcm13082256.

Lp(a) Levels in Relatives of Patients with Acute Coronary Syndrome and Elevated Lp(a): HER(a) Study

M Rosa Fernández-Olmo  1 , Magdalena Carrillo Bailen  1 , Mar Martínez Quesada  2 , Carmen Rus Mansilla  3 , Miriam Martin Toro  4 , Ana López Suarez  5 , Marta Lucas García  2 , Gustavo Cortez Quiroga  3 , Beatriz Calvo Bernal  4 , Samuel Ortiz Cruces  5 , Javier Torres Llergo  1 , Ana García Ruano  6 , Manuel Fernández Anguita  1 , Diego Franco  7 , Alberto Cordero  8
Affiliations

Lp(a) Levels in Relatives of Patients with Acute Coronary Syndrome and Elevated Lp(a): HER(a) Study

M Rosa Fernández-Olmo et al. J Clin Med. .

Abstract

Background: Lipoprotein(a) [Lp(a)] is a proatherogenic particle associated with increased cardiovascular risk. It is mainly genetically determined; so, the aim of our study is to evaluate the levels of Lp(a) in the relatives of a prospective cohort of patients who have suffered from an acute coronary syndrome (ACS) with Lp(a) ≥ 50 mg/dL. Methods: We conducted a multicenter prospective study, in which consecutive patients who had suffered from an ACS and presented Lp(a) ≥ 50 mg/dL and their first-degree relatives were included. Results: We included 413 subjects, of which 56.4% were relatives of the patients. Family history of early ischemic heart disease was present in 57.5%, and only 20.6% were receiving statin treatment. The family cohort was younger (37.5 vs. 59.1 years; p < 0.001), and 4% had ischemic heart disease and fewer cardiovascular risk factors. Mean Lp(a) levels were 64.9 mg/dL, 59.4% had levels ≥ 50 mg/dL, and 16.1% had levels ≥ 100 mg/dL. When comparing the patients with respect to their relatives, the mean level of Lp(a) was lower but without significant differences regarding the levels of LDLc, ApoB, and non-HDL. However, relatives with Lp(a) ≥ 50 mg/dL, had values similar to the group of patients with ACS (96.8 vs. 103.8 mg/dL; p = 0.18). No differences were found in Lp(a) levels in relatives based on the other lipid parameters. Conclusions: Overall, 59.4% of the first-degree relatives of patients who suffered from an ACS with Lp(a) ≥ 50 mg/dL also had elevated levels. Relatives with elevated Lp(a) had similar levels as patients.

Keywords: ACS; cardiovascular risk; cascade diagnosis; lipoprotein(a).

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Serum levels of Lp(a) in index patients and their relatives.
Figure 2
Figure 2
Distribution of Lp(a) and its correlation with low-density lipoprotein cholesterol (LDLc) levels (left) and ApoB (right).
Figure 3
Figure 3
Correlation between LDLc and ApoB in patients with Lp(a) levels< or >100 mg/dL.
See this image and copyright information in PMC

References

    1. Jawi M.M., Frohlich J., Chan S.Y. Lipoprotein(a) the Insurgent: A New Insight into the Structure, Function, Metabolism, Pathogenicity, and Medications Affecting Lipoprotein(a) Molecule. J. Lipids. 2020;2020:3491764. doi: 10.1155/2020/3491764. - DOI - PMC - PubMed
    1. Marcovina S.M., Albers J.J. Lipoprotein(a) measurements for clinical application. J. Lipid Res. 2016;57:526–537. doi: 10.1194/jlr.R061648. - DOI - PMC - PubMed
    1. Reyes-Soffer G., Ginsberg H.N., Berglund L., Duell P.B., Heffron S.P., Kamstrup P.R., Lloyd-Jones D.M., Marcovina S.M., Yeang C., Koschinsky M.L., et al. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement from the American Heart Association. Arterioscler. Thromb. Vasc. Biol. 2022;42:e48–e60. doi: 10.1161/ATV.0000000000000147. - DOI - PMC - PubMed
    1. Larsson S.C., Gill D., Mason A.M., Jiang T., Bäck M., Butterworth A.S., Burgess S. Lipoprotein(a) in Alzheimer, Atherosclerotic, Cerebrovascular, Thrombotic, and Valvular Disease: Mendelian Randomization Investigation. Circulation. 2020;141:1826–1828. doi: 10.1161/CIRCULATIONAHA.120.045826. - DOI - PMC - PubMed
    1. O’Donoghue M.L., Fazio S., Giugliano R.P., Stroes E.S.G., Kanevsky E., Gouni-Berthold I., Sabatine M.S. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation. 2019;139:1483–1492. doi: 10.1161/CIRCULATIONAHA.118.037184. - DOI - PubMed

LinkOut - more resources